Adriann Sax - 23 Jun 2023 Form 4 Insider Report for QSAM Biosciences, Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
23 Jun 2023, 16:30:47 UTC
Prior SEC filing
07 Mar 2022
Next SEC filing
02 May 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Adriann Sax

Key filing fact

Adriann Sax filed Form 4 for QSAM Biosciences, Inc. on 23 Jun 2023.

Key facts

  • This page summarizes Adriann Sax's Form 4 filing for QSAM Biosciences, Inc..
  • 1 reported transaction and 2 derivative rows are listed below.
  • Accepted by SEC: 23 Jun 2023, 16:30.

Change

  • Previous filing in this sequence was filed on 07 Mar 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

QSAM transaction

Common Stock

Award

Transaction value
$0
Shares
+10,455
Change %
Price
$0.000000
Shares after
10,455
Date
23 Jun 2023
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QSAM holding Derivative

Options to buy common stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
6,250
Date
23 Jun 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,250
Exercise price
$8.00
Footnotes
F2
QSAM holding Derivative

Options to buy common stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
18,750
Date
23 Jun 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
18,750
Exercise price
$10.00
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This award of shares is being made pursuant to the Issuer's restricted stock award agreement and is subject to a vesting schedule, such that a portion or all of this award of restricted stock may be forfeited in the future if certain milestones are not met

Footnote F2

The option vests annually in two equal installments beginning on 1/25/2023.

Footnote F3

The option vests annually in two equal installments beginning on 3/3/2023.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .